

Letters

International Cancer Congress:

The View from Argentina

The National Academy of Medicine of Buenos Aires, a body of 35 Academicians elected because they are indisputably among the best in the country, constitutes the highest medical authority in Argentina.

The Academy is troubled by the false and malicious reports spread abroad by the press misrepresenting the social situation in our country. According to the rumors so insidiously started, it would be unadvisable to attend the International Cancer Congress, to be held in Buenos Aires in October 1978, because of the general climate of public insecurity, the breaking of human rights laws, the persecution of scientists, and so forth.

In the presence of this pernicious propaganda against our country, the Academy finds it is its duty to inform the scientific community of the following facts:

1) Neither the members of this Academy nor the scientific, technical, or auxiliary staff that constitute its institutes (more than 200 persons) have ever had their personal freedom or their professional activities injured by the authorities or by isolated individuals.

2) During the latter years, the scientific activities of this Academy and its institutions have received the government's total support without any compulsion or compromise.

3) The climate of public security has substantially improved, and the kidnapping of personalities or functionaries formerly performed by the terrorists has ceased. We can affirm now, without distorting the truth, that Buenos Aires, as all Argentine cities, is as safe as any large European or American city.

4) At present, the universities and research institutes are places of quiet and fruitful work, in contrast to the agitation, the activism, and the persecution of professors and scientists that were so frequent before March 1976.

JOSÉ RIVAROLA

JULIO V. URIBURU

*Academia Nacional de Medicina de
Buenos Aires, Las Heras 3092,
Buenos Aires, Argentina*

Liposomes: European Research

Having read "Liposomes: Research applications grow" by Jean L. Marx (Research News, 10 Mar., p. 1056), I am concerned that relevant research in Europe, where the liposome drug carrier concept (as well as a great many of the current ideas) originated (1), is reported only vaguely and parenthetically. Below I describe some of the work being done on this side of the Atlantic.

The use of liposomes in biological and medical research is the outcome of efforts during the last decade to harness drug action through the use of suitable drug carriers. These are expected to optimize, in their various ways, drug-target contact and the ensuing pharmacological effect (2). A possible role for liposomes as a drug carrier first became apparent in 1971 in experiments designed to control drug distribution and action (3). Our interest was in enzyme replacement therapy of lysosomal storage diseases, which are characterized by the absence or deficiency of specific lysosomal enzymes and the accumulation of substances in the lysosomes. We found that liposomes were capable of transporting enzymes into the lysosomes (and perhaps other compartments of cells) where, after disruption of their carrier, enzymes could then act upon stored materials. These initial experiments demonstrated that liposomes can introduce agents into cells and alter their metabolism; they thus opened the way for numerous potential applications in cell biology and therapy.

Previous therapeutic attempts with exogenous enzymes in the treatment of lysosomal storage diseases had failed for various reasons, including immunogenicity of the foreign enzyme, its premature inactivation, and its inability to reach, or act in, afflicted cells. Experiments on animals indicated that circumvention of some of these problems appeared likely, and we tested the approach (4) in a patient with adult Gaucher's disease. During 2 years of treatment with liposome-entrapped glucocerebrosidase isolated from human placenta, the general health of the patient stopped deteriorating, the liver decreased in size, and pressure in the abdomen diminished. However, using liposomes in the treat-

ment of other lysosomal storage conditions (5) may be less hopeful. On the other hand, there is hardly anything else one can do with such diseases, and exploration of alternative relevant possibilities (6) offered by the system is worth pursuing.

One of the early proposed uses of liposomes was in cancer chemotherapy (7), where indiscriminate drug action prevents effective treatment. Studies of tissue distribution in humans and animals indicated that liposome-entrapped agents have considerable access to malignant tissues and that uptake of such agents by rapidly proliferating normal cells is diminished. Further, chemotherapy of mice with ascites tumors was promising in that cytotoxic drugs given by means of liposomes appeared more effective than free drugs in prolonging survival (8). Many laboratories are now engaged in studying how various liposomal preparations containing drugs interact with a number of tumor cell lines in vitro (1). At the same time, however, success in the management of cancer is ultimately dependent on the carrier finding its way to diseased areas. In this respect the roles of the liver and spleen, which normally intercept much of the injected dose; of blood components, which will alter the surface characteristics (and properties) of liposomes; and of the various anatomic barriers that exist between target cells and liposomes in the circulating blood are of paramount importance. Since "traveling" of liposomes to diseased areas precedes their interaction with relevant cells, resolution of such parameters warrants priority. Our recent work (9) shows that hepatic and splenic interference is diminished and the concentration of liposomal drugs in tumor areas is augmented when small liposomes (about 80 nanometers in diameter) are used. This is, of course, still a large size compared to that of most drug molecules, and free diffusion to tumors is bound to be restricted. But it is the size of the carrier along with other structural properties that prevents drugs from being wasted or from entering some of the more sensitive normal cells in the body. In addition, it may be possible to improve on the tendency of liposomes to concentrate in malignant tissues. We have shown (10) that enrichment of the liposomal surface with molecules (for example, antibodies to tumors) which exhibit a specific affinity for target cells, promotes selective association with the cells. Such association is an obligatory step for interiorization.

The avidity of the liver and the spleen for liposomes implies that the use of liposomes as carriers can be particularly helpful in the alleviation of diseases

Say goodbye to a couple of troublemakers.


If you use liquid nitrogen or dry ice in applications such as vapor freezing traps and low temperature baths, you know how expensive they are. And how difficult to handle and store.

What you may not know is that Neslab's CryoCool Refrigeration Units can do the

same job. Better. More efficiently. With virtually no bother. And at far less cost.

Hard to believe? Talk to some of the hundreds of satisfied CryoCool users, and you'll be a believer. We'll even send you a list of their names.

Send for our new catalogs on cooling systems, heat exchangers and/or constant temperature baths and circulators. Call if you need technical assistance with an applications problem.



NESLAB INSTRUMENTS, INC.
871 Islington Street
Portsmouth, NH 03801 U.S.A.
(603) 436-9444

Circle No. 47 on Readers' Service Card

COMBATING THE #1 KILLER

JEAN L. MARX and
GINA BARI KOLATA

The SCIENCE
Report on
Heart
Research

— a direct, unbiased report with information for all investigators in the field, makers of public policy, scientists and the general public.

\$17.00 casebound \$7.50 paperbound
10% discount to AAAS members

Send name, address and remittance to

AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE



Department B-3
1515 Massachusetts Avenue, NW
Washington, D.C. 20005

afflicting these two organs. Hepatic and splenic disorders are by no means few, and some of the tropical diseases affecting millions in the developing world are good examples. Research in this country (11) has shown that treatment of experimental visceral leishmaniasis with small amounts of liposome-entrapped antimonial drugs is as effective in killing the parasites in the liver as are much larger doses of free drugs. Success in this area of medicine would not only resolve problems of toxicity that prevent aggressive chemotherapy, it would also make therapy economically realistic for the countries involved.

Routes other than the intravenous have also been used for the administration of liposomes. Work at this laboratory (12) and elsewhere in England (13) suggests that insulin-containing liposomes given intragastrically can transport the hormone into the circulation and reduce blood glucose levels in diabetic rats. We have found that the effect is more pronounced when liposomes are made of certain semisynthetic phospholipids which, at the body temperature, are more resistant to pancreatic phospholipases or to detergents. Again, the implications for success in treating diabetic patients orally cannot be overemphasized. However, there are difficulties to overcome, among them, improving the absorption of liposomal insulin by the gut.

Local injection of liposomes as a means of drug administration is likely to be an early application mainly because of the avoidance of complications arising from intravenous use. Work at this laboratory (14) suggests that the need for a biocompatible immunological adjuvant that will make vaccination safer, more effective, and cheaper, may be satisfied by liposomes. Thus, immune response to liposome-entrapped bacterial and viral antigens administered intramuscularly was found to be much greater than when free antigens were used. Yet another possible means of local drug release is being investigated by workers in England who have shown (15) that specially tailored steroids anchored onto the liposomal membrane can, upon intraarticular injection into rabbits with experimental arthritis, decrease the temperature and the size of the joint to a much greater extent than can similar amounts of conventional steroids.

So far, experiments here and in Germany and experience with routine intravenous feeding with phospholipids suggest that liposomes of certain lipid compositions are almost certain to be safe (16). Indeed, in situations where some exploratory work in humans is

deemed essential (for example, liposome distribution in cancer patients when the anatomical and physiological circumstances of tumors cannot be duplicated in animals), their use should not be discouraged. There is, however, some concern with regard to the toxicity that drug-containing liposomes may induce as a result of an altered drug distribution, of an unsuspected novel way of drug action, or even because of the patient's reaction to the carrier. For instance, were one to administer (bovine or porcine) insulin-containing liposomes orally to normal volunteers, there could be a manifestation of the adjuvant property of the carrier with formed antibodies neutralizing the cross-reacting human insulin.

Progress in modifying cell structure and behavior by the use of liposomes in vitro has been, thanks to the obliging properties of the system, remarkable. It may be that the complexities of the living animal and ethical and practical difficulties in dealing with human subjects have delayed similar progress in medicine. This has caused some confusion as to the potential value of the carrier in helping to alleviate disease. But the need for controlled drug delivery is patently obvious; on this basis, liposomes (or their more sophisticated versions) along with other carriers are likely to play a significant role.

GREGORY GREGORIADIS

*Division of Clinical Investigation,
Clinical Research Centre, Harrow,
Middlesex, HA1 3UJ, England*

References

1. G. Gregoriadis, *N. Engl. J. Med.* **295**, 704 (1976); *ibid.*, p. 765; J. A. Fender and A. Romero, *Life Sci.* **20**, 1109 (1977); M. Finkelstein and G. Weissmann, *J. Lipid. Res.* **19**, 289 (1978).
2. G. Gregoriadis, *Nature (London)* **265**, 407 (1977).
3. — and B. E. Ryman, *Biochem. J.* **124**, 58 (1971); *Eur. J. Biochem.* **24**, 485 (1972); *Biochem. J.* **129**, 123 (1972); G. Gregoriadis and R. A. Buckland, *Nature (London)* **244**, 170 (1973).
4. P. E. Belchetz, I. P. Braidman, J. C. W. Crawley, G. Gregoriadis, *Lancet* **1977-I**, 116 (1977).
5. D. A. Tyrrell, B. E. Ryman, B. R. Keeton, V. Dubowitz, *Br. Med. J.* **2**, 88 (1976).
6. C. M. Cohen *et al.*, *Biochemistry* **15**, 452 (1976).
7. G. Gregoriadis, *FEBS Lett.* **36**, 292 (1973).
8. E. D. Neerunjun and G. Gregoriadis, *Biochem. Soc. Trans.* **2**, 868 (1974); Y.-E. Rahman, E. A. Cerny, S. L. Tollaksen, B. J. Wright, S. L. Nance, J. F. Thomson, *Proc. Soc. Exp. Biol. Med.* **146**, 1173 (1974).
9. G. Gregoriadis, E. D. Neerunjun, R. Hunt, *Life Sci.* **21**, 357 (1977).
10. G. Gregoriadis and E. D. Neerunjun, *Biochem. Biophys. Res. Commun.* **65**, 537 (1975).
11. C. D. V. Black, G. J. Watson, R. J. Ward, *Trans. R. Soc. Trop. Med. Hyg.* **71**, 550 (1977); R. R. C. New, M. L. Chance, S. C. Thomas, W. Peters, *Nature (London)* **272**, 55 (1978).
12. G. Dapergolas and G. Gregoriadis, *Lancet* **1976-II**, 824 (1976); *Biochem. Soc. Trans.* **5**, 1383 (1977).
13. H. M. Patel and B. E. Ryman, *FEBS Lett.* **62**, 60 (1976).
14. A. C. Allison and G. Gregoriadis, *Nature (London)* **252**, 252 (1974); G. Gregoriadis and A. C. Allison, *FEBS Lett.* **45**, 71 (1974).
15. J. T. Dingle *et al.*, *Nature (London)* **271**, 372 (1978).
16. G. Gregoriadis, *Ann. N.Y. Acad. Sci.*, in press.

21 JULY 1978

YOUR PROFESSIONAL REPUTATION DESERVES NOTHING LESS THAN OUR REPUTATION.

The world of Microscopy is a day after day world of challenges. Challenges to your skill, your interpretive powers, your ability to arrive at correct conclusions, and a challenge to your reputation.

That's why the professional chooses instruments of unquestioned precision that speed his work and leave him mentally and physically fresh for the next assignment. And he knows the economic importance and convenience of having a full range of accessories and services promptly available at all times, anywhere in the world.

With a Wild Heerbrugg Instrument at your fingertips, you can be absolutely confident that it meets every requisite of your profession.



**INSIST ON WILD
HEERBRUGG
MICROSCOPES.
NOTHING LESS.**

**WILD® WILD HEERBRUGG
HEERBRUGG INSTRUMENTS, INC.**

FARMINGDALE, NEW YORK 11735 • 516-293-7400

Wild Of Canada, Ltd. 881 Lady Ellen Pl., Ottawa 3, Ont.
Wild Of Mexico, Comercial Ultramar Sa, Colima 411, Mexico 6, D.F.
Circle No. 40 on Readers' Service Card